Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (163)

« Back to Publications

Editorial: Prediction of Survival in Hepatocellular Cancer—Rise and Fall of the Machines

Pavlides M., (2026), Alimentary Pharmacology & Therapeutics

Lowering the bar? Noninvasive tests for identifying significant fibrosis in metabolic dysfunction-associated steatotic liver disease.

Pavlides M. and Appiah E., (2026), Pol Arch Intern Med, 136

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

Middelburg TE. et al, (2026), JHEP Rep

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

Cobbold JF. et al, (2026), Lancet Gastroenterol Hepatol

Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.

Selvaraj EA. et al, (2026), BMC Med Imaging, 26

Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study.

Zhao J. et al, (2025), MedComm (2020), 6

Imaging Biomarkers in Metabolic Dysfunction Associated Steatotic Liver Disease

Gul D. and Pavlides M., (2025), Current Hepatology Reports, 24

Investigation of the Effect of Isotonic Drinks on Quantitative MRI Markers of the Liver and Spleen.

Pittas NN. et al, (2025), NMR Biomed, 38

Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Koutoukidis DA. et al, (2025), J Cachexia Sarcopenia Muscle, 16

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Feng G. et al, (2025), Clin Gastroenterol Hepatol, 23, 785 - 796

Pilot feasibility study to determine the utility of direct access and quantitative magnetic resonance cholangiopancreatography (MRCP) in the assessment of suspected acute biliary or ductal gallstone presentations.

Novak A. et al, (2025), BMC Gastroenterol, 25

Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.

Vali Y. et al, (2025), Liver Int, 45

Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis.

Dai J. et al, (2025), PLoS One, 20

Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.

Gharibzadeh S. et al, (2025), EClinicalMedicine, 79

Validation of quantitative magnetic resonance cholangiopancreatography metrics in the prediction of event-free survival in primary sclerosing cholangitis: an International PSC study group collaboration

Middelburg T. et al, (2025), JOURNAL OF HEPATOLOGY, 82

Load More

1
2
3
4
5
6
7
...
»